bims-instec Biomed News
on Intestinal stem cells and chemoresistance in colon cancer and intestinal regeneration
Issue of 2026–05–24
twenty papers selected by
Maria-Virginia Giolito, Université Catholique de Louvain



  1. Cancer Cell. 2026 May 21. pii: S1535-6108(26)00220-5. [Epub ahead of print]
      KRAS is mutationally activated in 45%-50% of colorectal cancer (CRC) cases, and while KRAS-targeted therapies have shown clinical promise, drug resistance limits their efficacy. To explore the mechanisms underlying KRAS inhibitor resistance, we use targeted exome sequencing and spatial transcriptomics on patient-matched CRC biopsies following combined treatment with KRASG12C and EGFR inhibitors. We show that acquired genetic events are identified in most patients at progression but are often subclonal and coexist with transcriptional adaptive states. Mesenchymal, YAP, and fetal-like transcriptional signatures predominate in resistant tumors, while inflammatory programs are induced early on treatment. Single-cell spatial analysis reveals intratumoral heterogeneity, with diverse adaptive states in different zones of individual tumors. Using human and murine organoid models, we show that drug-induced inflammatory programs are, at least in part, cancer-cell autonomous, and precede the emergence of drug resistance. We identify TBK1 as a target to abrogate the inflammatory adaptive phase and enhance responses to KRAS inhibition.
    Keywords:  CRC; KRAS; TBK1; inflammation; plasticity
    DOI:  https://doi.org/10.1016/j.ccell.2026.04.009
  2. Cold Spring Harb Perspect Biol. 2026 May 18. pii: a041915. [Epub ahead of print]
      The Hippo signaling pathway, first identified in Drosophila, is a conserved regulator of organ size and tissue homeostasis that balances proliferation and apoptosis. In mammals, its core kinases mammalian Sterile 20-like kinases 1 and 2 (MST1/2) and large tumor suppressor kinases 1 and 2 (LATS1/2) restrict the transcriptional coactivators Yes-associated protein 1 (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ), whose nuclear translocation drives cell proliferation and survival. In the intestine, YAP/TAZ activity is normally repressed to maintain homeostasis, but transient activation following injury promotes regeneration. Injury-induced YAP signaling triggers a regenerative transcriptional program marked by fetal gene re-expression and the emergence of Clusterin (Clu)-positive revival stem cells (revSCs), which restore leucine-rich repeat-containing G-protein-coupled receptor 5-positive (Lgr5+) intestinal stem cells and epithelial integrity. Cross talk between Hippo, Wingless-related integration site (WNT), transforming growth factor β (TGF-β), and p53 signaling orchestrates this dynamic repair process, with precise temporal control of YAP essential for successful regeneration. Dysregulation of these interactions contributes to colorectal cancer tumorigenesis, highlighting the Hippo pathway as a central hub linking intestinal homeostasis, regeneration, and cancer.
    DOI:  https://doi.org/10.1101/cshperspect.a041915
  3. EMBO Mol Med. 2026 May 19.
      Molecular therapies targeting the EGFR/MAPK pathway have improved outcomes in colorectal cancer (CRC), yet acquired resistance remains a major clinical challenge. Oncogenic signaling can activate stress response pathways that sustain tumor survival under therapeutic pressure. Among these, the DNA damage response (DDR) maintains genomic integrity and may represent a targetable vulnerability in resistant tumors. To investigate this, we developed a preclinical platform of CRC models with acquired resistance to anti-EGFR agents ("ARes platform"). A targeted pharmacological screen of DDR inhibitors identified WEE1 kinase as a leading therapeutic candidate. Validation in xenograft models and patient-derived organoids confirmed that anti-EGFR-resistant CRCs retained, and in some cases increased, sensitivity to WEE1 inhibition. Mechanistically, resistant cells exhibited elevated DNA damage, heightened replication stress, and accelerated mitotic entry, culminating in cell death upon WEE1 blockade. These findings establish WEE1 as a promising therapeutic target in CRC with acquired resistance to EGFR inhibition and support the clinical evaluation of WEE1 inhibitors, alone or combined with DNA-damaging agents, for patients progressing on anti-EGFR-based therapies.
    DOI:  https://doi.org/10.1038/s44321-026-00434-4
  4. Mol Metab. 2026 May 20. pii: S2212-8778(26)00066-9. [Epub ahead of print] 102382
      Cancer cells dynamically reprogram their metabolism to adapt to changing microenvironmental conditions during tumor growth and metastatic dissemination. Metastasis of solid tumors-the principal cause of cancer-related mortality-is often driven through activation of epithelial-mesenchymal transition (EMT), regulated by the transcription factor ZEB1, which is frequently upregulated during tumor progression. To investigate the role of metabolic plasticity in metastasis, we employed murine pancreatic ductal adenocarcinoma (PDAC) cell lines with distinct EMT states, ZEB1 expression and lung colonization capacities. Highly plastic epithelial-type cancer cells (KPCepi) efficiently colonize the lung, whereas Zeb1-deficient cancer cells (KPCZ) with compromised metabolic plasticity show markedly reduced colonization, correlated with absent glycolytic reserve, mitochondrial dysfunction, and reduced anti-oxidant metabolite levels. Interestingly, mesenchymal-type cancer cells (KPCmes) also exhibit poor lung colonization despite retaining normal glycolytic capacity and a high proportion of functional mitochondria; however, similar to KPCZ cells, they display diminished levels of detoxifying metabolites. Low metastatic capacity correlates with increased susceptibility to ferroptosis even in epithelial-type KPCZ cells, indicating a limited ability to counteract reactive oxygen species under stress. Together, these findings demonstrate that metabolic plasticity and redox homeostasis are essential prerequisites for efficient lung colonization. Thus, concurrent targeting of metabolic adaptability and redox buffering may represent a promising strategy to prevent metastasis in aggressive PDAC tumors.
    Keywords:  Cancer; Cellular plasticity; Epithelial-to-mesenchymal transition; Ferroptosis; Glycolysis; Metabolism; Metastasis; Mitochondria; Pancreatic ductal adenocarcinoma (PDAC); Redox balance
    DOI:  https://doi.org/10.1016/j.molmet.2026.102382
  5. J Clin Invest. 2026 May 21. pii: e197772. [Epub ahead of print]
      Cancers reflect aberrant growth and differentiation of normal cell populations. Biological understanding of small intestine neuroendocrine tumors (SI-NETs) is hampered because their closest normal counterparts, enteroendocrine cells (EECs), constitute tiny fractions of intestinal epithelium. Recent characterization of adult human EEC ontogeny from intestinal stem cells can help overcome that limitation. Transient expression of transcription factor gene ASCL1 normally ensures proper timing and fidelity of well-differentiated EECs, which express NEUROD1. Here we report that SI-NETs resembled mature enterochromaffin cells; however, individual tumor cells co-expressed stem/progenitor genes, harboring each differentiation state along the EEC trajectory except ASCL1+ precursors. We found that enhancers normally active, and others inactive, during EEC differentiation underlie aberrant SI-NET gene activity. SI-NETs uniformly expressed NEUROD1 but lacked ASCL1, owing to inaccessible chromatin and repressive H3K27me3 marking at the ASCL1 locus. Multiple cyclin-dependent kinase inhibitor (CDKi) genes were similarly silenced, other than CDKN1B, the only gene recurrently mutated in SI-NETs. Deletion of CDKN1B altered cell cycle kinetics during human EEC differentiation, and deletions of ASCL1 or CDKN1B activated certain genes that are expressed in SI-NETs but not in the normal EEC trajectory. We propose that a limited CDKi repertoire and absence of ASCL1-dependent constraints on EEC maturation together explain unique SI-NET characteristics.
    Keywords:  Adult stem cells; Cancer; Development; Gastroenterology; Neuroendocrine regulation; Oncology
    DOI:  https://doi.org/10.1172/JCI197772
  6. Nat Commun. 2026 05 18. pii: 4406. [Epub ahead of print]17(1):
      DKC1, a key coordinator of RNA modification and telomerase activity, has been implicated in colorectal cancer (CRC), yet its role in disease pathogenesis remains incompletely understood. We show that DKC1 drives CRC by promoting cell cycle progression, suppressing apoptosis, conferring stemness and drug resistance. Elevated DKC1 in CRC associates with poor prognosis and WNT-enriched Consensus Molecular Subtype 2 gene signature. Mechanistically, canonical WNT-signaling forms a feedback loop with DKC1, driving its expression and oncogenic activity. Comprehensive transcriptomic and lipidomic analyses reveal perturbed sphingolipid metabolism and abundance of specific very-long-chain fatty acid ceramides. Further, a regulatory axis involving DKC1 and SOX2 drives the expression of SGPP2, a critical sphingolipid metabolism mediator. Importantly, DKC1-mediated sphingolipid dysregulation promotes first-line chemoresistance, and FOLFOX-resistant patient-derived organoids effectively respond to DKC1 and WNT signaling inhibitors. Conclusively, we identify the DKC1/WNT axis as a therapeutic target in therapy-resistant CRC and underscore complex sphingolipids as promising plasma-based biomarkers.
    DOI:  https://doi.org/10.1038/s41467-026-72800-2
  7. bioRxiv. 2026 May 06. pii: 2026.05.03.722515. [Epub ahead of print]
       Background and Aims: The tumor microenvironment in colorectal cancer (CRC) is richly innervated, yet the contribution of the enteric nervous system (ENS) to CRC biology remains poorly defined. ENS neurons express proenkephalin (PENK), which can be processed by proprotein convertase 1/3 (PCSK1) to generate Methionine-enkephalin (M-ENK), a bioactive peptide with growth-regulatory potential. We hypothesized that an ENS-derived PCSK1-M-ENK axis restrains CRC proliferation through opioid growth factor receptor (OGFr) signaling and is modulated by stress-associated glucocorticoid receptor (GR) signaling and GLP1 receptor (GLP1R) activity.
    Methods: Publicly available human CRC single-cell RNA-sequencing datasets were analyzed for OGFr expression. PCSK1 and M-ENK expression in murine ENS and tumor-associated tissue was assessed by immunofluorescence. Functional studies were performed using murine CRC organoids, and primary murine ENS neurons in mono- and co-culture. CRC proliferation was quantified by EdU incorporation following treatment with recombinant M-ENK, recombinant PCSK1, OGFr synthetic ligand naloxone, or PCSK1 inhibitors. Effects of dexamethasone and liraglutide on PCSK1 expression in ENS-containing murine tissue were evaluated.
    Results: OGFr was enriched in CRC cells and positively associated with KRAS gene expression. A subset of adult murine colonic myenteric neurons expressed PCSK1 and M-ENK. M-ENK dose-dependently suppressed proliferation of CRC organoid cells. ENS neurons also suppressed CRC proliferation in a PCSK1-dependent manner. Dexamethasone reduced, whereas liraglutide increased, PCSK1 expression.
    Conclusions: These findings define a previously unrecognized ENS-derived neuro-oncologic pathway that is associated with reduced CRC cell proliferation and identify the GR/GLP1R-PCSK1-M-ENK axis as a potentially actionable therapeutic node.
    Summary: This study identifies a neuronal PCSK1 - M-ENK pathway in the ENS that directly suppresses colorectal cancer growth through local OGFr activation, revealing a previously unrecognized neuropeptidergic mechanism of tumor control within the intestinal microenvironment.
    DOI:  https://doi.org/10.64898/2026.05.03.722515
  8. Int J Biol Sci. 2026 ;22(9): 4956-4975
      Class IIa histone deacetylase 7 (HDAC7) regulates transcription primarily through scaffolding functions, but its molecular mechanisms in cancer pathogenesis remain incompletely understood. Here, we establish HDAC7 as a key epigenetic regulator in colorectal cancer (CRC). HDAC7 is overexpressed in CRC tumors and correlates with advanced disease stages, lymph node metastasis, and poor patient survival. Mechanistically, HDAC7 scaffolds a repressive complex with HDAC3 and the stress-responsive transcription factor ATF3. This reduces H3K27ac/H3K18ac occupancy and blocks BRD4/RNA polymerase II (Pol II) recruitment at ATF3 regulatory regions to epigenetically silence its transcription. Consequently, this repression inactivates ATF3's tumor-suppressive functions, activating oncogenic PI3K-Akt signaling while suppressing the Hippo pathway. Genetic depletion or pharmacological inhibition of HDAC7 disrupts this repressive complex, triggering a functional switch in ATF3. This promotes BRD4/Pol II recruitment and H3K27ac enrichment at the ATF3 locus, enabling ATF3 to undergo transcriptional self-activation. Reactivated ATF3 suppresses CRC proliferation and survival by downregulating Bcl-2, upregulating p21 (CDKN1A) to induce cell cycle arrest, promoting caspase-3-mediated apoptosis, and inhibiting PI3K-Akt signaling. Xenograft studies confirm that HDAC7 depletion suppresses tumorigenicity in vivo. Our work identifies HDAC7 as a molecular mediator that governs ATF3's functional plasticity through competitive cofactor recruitment, positioning HDAC7 inhibition as a therapeutic strategy to reactivate ATF3-mediated tumor suppression in CRC.
    Keywords:  ATF3; HDAC7; class IIa HDAC; colorectal cancer; epigenetic repression; scaffold protein
    DOI:  https://doi.org/10.7150/ijbs.121348
  9. Eur J Immunol. 2026 May;56(5): e70204
      Colorectal cancer (CRC) patients are frequently diagnosed with metastases to the peritoneal cavity. These patients have a dismal prognosis and only limited therapeutical benefits. Solid tumors, including CRC, often display elevated levels of sialylated glycan structures, acting as immune checkpoints for immune evasion. However, the detrimental effects of tumor sialylation on antitumor immunity at the peritoneal site remain unexplored. We uncovered that sialylation is higher in peritoneal metastases (PM) compared with primary CRC or liver metastases. Intraperitoneal injection of sialic acid-deficient CT26 CRC cells led to significantly less peritoneal tumor development and a lower peritoneal cancer index (PCI) score. Sialic acid-devoid tumors harbored higher numbers of live CD45+ cells, and the myeloid compartment of desialylated tumors showed increased levels of MHC-II+ macrophages and dendritic cells and significantly fewer neutrophils and CD206+ macrophages, correlating with a lower PCI score. In conclusion, the absence of sialylated glycans reprograms antitumor immunity and reduces tumor formation at the peritoneal site.
    Keywords:  colorectal cancer; peritoneal metastasis; sialic acids; tumor immunity
    DOI:  https://doi.org/10.1002/eji.70204
  10. EMBO J. 2026 May 20.
      Intestinal stem cells (ISCs) continuously renew the gut epithelium by producing specialised cell types, yet the mechanisms that couple ISC renewal with lineage commitment remain poorly characterised. Here, we identify a self-limiting transcriptional program, mediated by the zinc-finger transcription factor Chronophage (Cph), that promotes both ISC maintenance and differentiation into enteroendocrine (EE) cells in the Drosophila midgut. Cph expression is transiently induced by the proneural factor scute at the onset of ISC-to-EE specification. Genetic and single-cell transcriptomic approaches revealed that Cph is required to reprogramme ISCs and sustain normal lifespan. Cph binds to genes involved in proliferation and differentiation, and directly represses its own expression. This autoinhibitory feedback safeguards ISCs from accumulating autophagosomes and undergoing cell death, thus preserving ISC function. Our findings uncover a key regulatory mechanism that balances stem cell maintenance and differentiation, highlighting principles relevant to regenerating tissues.
    DOI:  https://doi.org/10.1038/s44318-026-00808-x
  11. Front Pharmacol. 2026 ;17 1706106
      Primary human intestinal epithelial cells (IECs) require microenvironments that reproduce various in vivo cues to maintain survival, differentiation, and function in vitro. In this study, we investigated how intestinal stem cell (ISC)-derived monolayers respond to biomimetic substrates and shear stress using 3D-printed hydrogels based on bioactive decellularized and methacrylated small intestinal submucosa (dSIS-MA) integrated into a custom millifluidic system. Extensive bulk RNA sequencing experiments revealed that, compared with Matrigel-coated tissue culture plastic, dSIS-MA hydrogels supported survival- and differentiation-related signaling, stabilized gene expression over time, and promoted absorptive lineage maturation while reducing crypt-associated signatures. By applying dynamic culture conditions to the hydrogel system, IECs underwent transcriptional remodeling, characterized by activation of metabolic and immune pathways. Longitudinal analysis further indicated that shear stress enhanced metabolic pathway-associated gene expression and promoted differentiation toward absorptive lineages. These findings establish dSIS-MA hydrogels with controlled fluid flow as a biomimetic in vitro model that supports survival, maturation of human IECs and enables transcriptional adaptation to defined biochemical and mechanical cues, supporting future applications in disease modelling, drug testing, and regenerative medicine.
    Keywords:  biomimetic; epithelial cells; hydrogel; millifluidics; organoids; shear stress; small intestine
    DOI:  https://doi.org/10.3389/fphar.2026.1706106
  12. JCO Precis Oncol. 2026 May;10(5): e2501229
       PURPOSE: The EXOsome and cell-free microRNAs (miRNAs) of anti-epidermal growth factor receptor (EGFR) Resistance (EXONERATE) study previously developed and validated a liquid biopsy to predict the efficacy of first-line anti-EGFR therapy in metastatic colorectal cancer (mCRC) from treatment-naïve blood samples. This study evaluates the performance of the EXONERATE assay during therapy as a tool for monitoring the emergence of anti-EGFR resistance before it becomes clinically or radiologically apparent.
    METHODS: Retrospective, single-center, longitudinal, REMARK-compliant biomarker study assessing the ability of a liquid biopsy to predict response to anti-EGFR monoclonal antibodies and to track resistance development longitudinally. Fifty-two patients with RAS wild-type mCRC provided 142 plasma samples during administration of first-line anti-EGFR-based therapy.
    RESULTS: Baseline EXONERATE scores predicted response with 83.3% specificity and 77.3% sensitivity (area under the receiver operating characteristic curve [AUROC] = 89.4%). Longitudinal analyses demonstrated that biomarker changes closely tracked tumor burden and anticipated clinical and radiological progression, outperforming conventional tumor markers CEA and CA19-9. Stepwise optimization produced a reduced panel (four cell-free-miRNAs and five exo-miRNAs), EXONERATE-Tracking Response and Clinical Evolution (TRaCE), which retained high predictive accuracy (AUROC = 94.4%) while enabling more practical, repeated monitoring. EXONERATE-TRaCE values increased during the 3 months preceding the first clinical or radiological evidence of progression and reliably detected early progression in both left- and right-sided tumors, including patients with lung metastases, and identified resistance up to 3 months before radiological confirmation.
    CONCLUSION: EXONERATE-TRaCE extends the predictive utility of the original EXONERATE assay into a practical monitoring tool. This liquid biopsy detects emerging anti-EGFR resistance earlier than conventional markers and may inform treatment monitoring and support timely clinical decision making in mCRC.
    DOI:  https://doi.org/10.1200/PO-25-01229
  13. Cancer Treat Res. 2026 ;195 155-174
      Cancer stem cells (CSCs) are a subset of tumor cells that exhibit self-renewal, differentiation potential, and resistance to conventional therapies. One of the characteristic traits of CSCs is their metabolic flexibility, with the ability to adapt energy production and biosynthesis in the context of low oxygen, limited nutrients, and therapy-driven stress. This adaptability allows them to survive, advances tumor development, and results in relapse after treatment.CSCs can switch between glycolysis and oxidative phosphorylation (OXPHOS) dynamically in different biological contexts. CSCs mainly produce ATP and synthesize nucleotides, amino acids, and lipids through glycolysis in hypoxia. OXPHOS is important for the maintenance of quiescent cells, for reducing reactive oxygen species (ROS) production, and supports long-term survival and tumor initiation. In addition to glucose, CSCs utilize lipid and amino acid metabolism. Fatty acid oxidation provides energy during stress, while glutamine, serine, and glycine support biosynthesis, redox homeostasis, and epigenetic control, collectively enhancing survival and therapy resistance. CSCs also rely on lipid and amino acid metabolism, in addition to glucose. Fatty acid oxidation is a source of energy during stress, and glutamine-, serine-, and glycine-derived metabolic products contribute to promoting biosynthesis for redox homeostasis, epigenetic regulation, and survival/therapy resistance. The tumor microenvironment (TME) dictates CSCs' metabolism through cross talk with fibroblasts, immune cells, and components of the extracellular matrix. Metabolic interplay, e.g., reverse Warburg effect, allows CSC to consume stromal metabolites, facilitating the promotion of tumor and resistance to therapy. Targeting of CSC metabolism, via glycolytic and mitochondrial inhibitors, lipid metabolism originated blockers, or amino acids modulators can perturb the survival of CSCs and increase tumor sensitivity to classical therapies. In this aspect, the application of combinatorial therapy was able to provide additional benefit by addressing both proliferative and quiescent CSC.In conclusion, metabolic reprogramming underpins CSC survival, drives therapy resistance, and promotes tumor progression. Exploiting these metabolic adaptations provides a promising strategy for achieving long-lasting and effective cancer therapies.
    Keywords:  Cancer stem cells; Glycolysis; Metabolic reprogramming; Metabolic targeting; Reverse Warburg effect; Tumor microenvironment
    DOI:  https://doi.org/10.1007/978-3-032-21861-2_8
  14. BMC Cancer. 2026 May 19. pii: 628. [Epub ahead of print]26(1):
       BACKGROUND: Colorectal cancer (CRC) frequently exhibits hypoxic regions due to poor vascularization, leading to the stabilization of hypoxia-inducible factor 1 alpha (HIF-1α). Moreover, mutations in the tumour suppressor p53 occur in approximately half of all CRCs. While the individual roles of both transcription factors in tumour cell survival are well characterized, their interaction and its influence on the metabolic adaptation of CRC cells under hypoxic stress remain unclear.
    METHODS: Using HCT116 CRC cells with targeted deletions of TP53 and HIF1A, we examined the effects of p53 loss on HIF-1 signalling and the respective consequences for metabolic adaptation as well as the survival of CRC cells under moderate (1% O₂) and severe (0.1% O₂) hypoxia.
    RESULTS: Severe hypoxia stabilized p53 protein levels despite the transcriptional repression of TP53, possibly through posttranslational mechanisms and dependent on nutrient availability. In contrast to the assumption that p53 is transcriptionally inactive under hypoxia, we observed stable expression of p53 target genes (P21, BAX) under severe hypoxia, indicating functional transactivation. Loss of p53 impaired the early induction of HIF-1 target genes (VEGF, PHD2), although HIF-1α protein levels and DNA binding were unaffected, suggesting a coactivator role for p53. Furthermore, compared with wild-type cells, p53-deficient cells presented delayed but exaggerated expression of glycolytic genes, including Glucose Uptake Transporter 1 (GLUT1), Phosphofructokinase Liver-Type (PFKL) and Lactate Dehydrogenase A (LDHA), under hypoxia, with no impairment of glycolytic function or cell viability. Remarkably, even HIF1A knockout cells preserved glycolysis, whereas glycolytic genes were significantly downregulated, indicating HIF-1-independent metabolic compensation.
    CONCLUSION: Our findings position p53 as a temporal gatekeeper and key regulator of hypoxic adaptation in CRC cells, coordinating early gene induction and metabolic responses. The ability of CRC cells to maintain glycolysis despite the loss of p53, respectively, HIF-1α underscores the existence of compensatory HIF-independent pathways. Targeting these alternative circuits may represent a promising strategy in hypoxic, p53-deficient CRC.
    Keywords:  Colorectal cancer; Glycolysis; HIF-1α; Hypoxia; Metabolic adaptation; P53; Transcriptional regulation
    DOI:  https://doi.org/10.1186/s12885-026-16184-y
  15. Cancer Discov. 2026 May 19.
      Neutrophils are major players in innate immune immunity. However, their landscape and functions in colorectal cancer liver metastasis (CRLM) remain poorly understood. Here, using single-cell RNA sequencing and spatial-enhanced-resolution-omics-sequencing (Stereo-seq), we provide a comprehensive transcriptional landscape of tumor-associated neutrophils (TANs) in CRLM. Our analysis reveals that a terminally differentiated pro-tumor neutrophils subset (TAN1), characterized by a glycolysis signature and a senescent phenotype, is significantly enriched in liver metastasis and associated with poor prognosis. Mechanistically, TAN1 arises from other TAN subsets through the upregulation of BHLHE40, driven by glucose deprivation in the metastatic microenvironment. Functionally, TAN1 promotes angiogenesis via VEGFA and recruits immunosuppressive macrophages through potential CCL3L1-CCR1 signaling, thereby fostering an angiogenic immunosuppressive niche. As a result, neutrophil-specific knockout of Bhlhe40 in mice significantly promotes anti-tumor immunity and suppresses tumor growth. In sum, our data uncover the critical role of BHLHE40+ senescent-like neutrophils in shaping the immunosuppressive microenvironment of CRLM.
    DOI:  https://doi.org/10.1158/2159-8290.CD-25-0820
  16. Sci Adv. 2026 May 22. 12(21): eadx3959
      Enhancing the specificity of oncogenic pathway inhibition in cancer cells improves both efficacy and tolerability of anticancer therapies. Hyperactivated Wnt signaling is a key driver in cancers such as colorectal cancer and pancreatic ductal adenocarcinoma, but its direct inhibition is limited by severe toxicities due to the importance of Wnt signaling in normal tissues, particularly the gut and bone. To address this challenge, we designed bispecific antibodies that selectively target surface proteins of oncogenic signaling pathways in tumor cells while sparing normal cells. Using single-cell technologies, we identified tumor-specific receptors, including tumor-associated calcium signal transducer 2 (TROP2), which are absent in cells reliant on Wnt signaling. Our TROP2-targeted anti-Frizzled bispecific antibody effectively inhibited Wnt signaling in preclinical models with minimal effect on normal intestinal tissue. Expanding this approach, we developed tumor-targeted, toxicity-sparing bispecific antibodies against fibroblast growth factor receptor 1 (FGFR1) and epidermal growth factor receptor (EGFR). This work establishes a framework for designing targeted therapeutics that minimize cell type-specific toxicities in cancer and other diseases.
    DOI:  https://doi.org/10.1126/sciadv.adx3959
  17. Cell Death Discov. 2026 May 22.
      Tumor metabolism, a crucial component in cancer progression, represents a potential prognostic and diagnostic platform in cancer detection. Here, we show that patient-specific stromal mesenchymal cells exhibit distinct behaviors in promoting either tumor growth or dissemination. Tumor-associated fibroblasts (TAFs) isolated from non-metastasized colorectal adenocarcinomas predominantly supported cancer cell proliferation, whereas TAFs isolated from metastatic adenocarcinomas facilitated cancer cell migration. An in vitro analysis of stromal paracrine factors revealed that variations in mitochondrial activity and the secretion of specific metabolites were closely associated with distinct tumor-stroma interactions. Among the oncometabolites identified, we validated amino acid expression in urine samples from 19 colon cancer patients to assess their potential as diagnostic biomarkers. Our results showed patient-specific alterations in oncometabolite expression, which were significantly different from those of healthy control individuals. The specificity, sensitivity, and accuracy analysis indicated 93-100% specificity, 74-82% sensitivity, and 84-89% accuracy of single metabolites in distinguishing cancer patients from healthy controls. While no false negatives were observed, urine samples from nine patients with various inflammatory conditions (including diverticulitis, appendicitis, and chronic gastritis) yielded false positives. Sensitivity analysis and the t-Distributed Stochastic Neighbor Embedding (t-SNE) nonlinear dimensionality reduction technique revealed distinct metabolite profiles for healthy controls, colon cancer patients, and patients diagnosed with inflammation. Overall, our findings suggest that the identified oncometabolites, when integrated into a biomarker panel, hold promise as a novel non-invasive tool for screening individuals at risk of cancer and inflammatory malignancies.
    DOI:  https://doi.org/10.1038/s41420-026-03172-1
  18. Cancer Cell Int. 2026 May 20.
       BACKGROUND: One of the leading causes of poor prognosis in colorectal cancer (CRC) patients is the presence of colorectal cancer-initiating cells (CCICs). The tumor microenvironment (TME) plays a role in the acquisition of CCICs characteristics. However, the underlying mechanisms remain unclear.
    METHODS: Candidate molecules were identified by analyzing the differentially expressed genes (DEGs) between spheroid and planar cells, as well as between CD24+CD44+ cells and CD24-CD44- cells. The relationship between prognosis and ARRDC4 was assessed using RT-qPCR and Western blot assays. Mitochondrial analysis was conducted to examine the role of ARRDC4 in metabolic reprogramming. Coimmunoprecipitation (co-IP) assays with exosomes were performed to investigate the downstream molecule WWP1. Clinical samples were collected for validation.
    RESULTS: We identified a novel TME-responsive protein involved in the reprogramming of CRC cells. ARRDC4 was upregulated in CCICs and responsive to the TME. In CCICs, ARRDC4 translocated to the mitochondrial matrix, where it reprogrammed lipid metabolism. Upregulation of ARRDC4 promoted exosome secretion. WWP1 primarily binds to ARRDC4 and is released through exosomes. Released WWP1 is taken up by surrounding CRC cells, inhibiting epithelial-mesenchymal transition (EMT) and migration.
    CONCLUSION: TME-responsive ARRDC4 inhibits CRC progression by regulating metabolic reprogramming and exosome secretion. Increased WWP1 in ARRDC4+ CCIC-derived exosomes suppresses CRC metastasis. We identified ARRDC4/WWP1 pathway as a novel mechanism and potential therapeutic target for CRC progression.
    Keywords:  ARRDC4; Colorectal cancer progression; Colorectal cancer-initiating cells; Exosomes; Tumor microenvironment
    DOI:  https://doi.org/10.1186/s12935-026-04339-7
  19. Free Radic Biol Med. 2026 May 20. pii: S0891-5849(26)00772-0. [Epub ahead of print]253 36-55
      Dietary westernization exacerbates polyunsaturated fatty acid-mediated intestinal inflammation, though the mechanistic links between arachidonic acid (AA)-induced gut metabolic dysregulation and glutathione peroxidase 4 (GPX4)-regulated inflammatory modulation ‌require further elucidation. Employing both lipopolysaccharide (LPS)-induced and dietary AA-fed murine models, we revealed profound alterations in oxylipin profiles and catalytic enzyme expression, which were effectively alleviated by selenium (Se) supplementation via GPX4 upregulation. The LPS model was used to identify inflammation-associated alterations in AA metabolism, while the chronic dietary AA model was applied to further evaluate the pathological role of sustained AA metabolic activation in intestinal injury. Genetic approaches (Gpx4+/-IEC and Gpx4+/-Mye) identified intestinal epithelial cells GPX4 as the central regulator orchestrating AA metabolic flux and inflammatory cascades. Single-cell RNA sequencing analysis demonstrated that while AA exposure alone induced moderate enterocyte reduction, concomitant IEC-Gpx4 knockdown markedly potentiated this depletion. Notably, ferrostatin-1 administration alleviated oxylipin dysregulation and inflammatory activation triggered by dietary AA treatment combined with IEC-Gpx4 knockout. IEC-macrophage co-culture experiments demonstrated that IEC-Gpx4 not only corrects AA-induced oxylipin disturbances but also suppresses chemokine/cytokine release and prevents Slamf7+ pro-inflammatory macrophage polarization. Collectively, these findings establish the Se-GPX4-oxylipin axis as a fundamental regulatory circuit in intestinal inflammation, providing mechanistically grounded therapeutic strategies for inflammatory bowel diseases.
    Keywords:  Arachidonic acid; Intestinal inflammation; Oxylipins; Selenium-GPX4 axis
    DOI:  https://doi.org/10.1016/j.freeradbiomed.2026.05.292
  20. Gut Microbes. 2026 Dec 31. 18(1): 2670854
      Strains of Limosilactobacillus reuteri have been used to prevent or treat various conditions; however, the mechanisms by which they exert beneficial effects are not completely understood. Infant colic is one example in which L. reuteri DSM 17938 reduces clinical symptoms. While the etiology of colic is unknown, abnormal melatonin levels in infants have been suggested as a possible contributor. L. reuteri DSM 17938 has been shown to produce adenosine from AMP via production of the extracellular enzyme 5'ectonucleotidase (5'NT). Adenosine is a potent signaling molecule that impacts several important aspects of host physiology, including the release of melatonin from the pineal gland in the brain. A second major source of melatonin production is enteroendocrine cells in the intestine. We hypothesized that the adenosine generated via the 5'NT activity of L. reuteri DSM 17938, would stimulate melatonin release from human intestinal organoids. Here, we characterized the growth conditions that impact L. reuteri DSM 17938 5'NT activity, including carbon source utilization and required metal cofactors. We found zinc to be an essential cofactor for 5'NT activity by L. reuteri and observed carbon utilization altered 5'NT activity levels. Stachyose and raffinose increased levels of 5'NT activity while sucrose decreased 5'NT activity. We demonstrated that L. reuteri DSM 17938 stimulates melatonin release from pediatric human intestinal organoids in a 5'NT-dependent manner. Surprisingly, adenosine was necessary, but not sufficient, for the induction of epithelial melatonin release, thereby suggesting that an additional secreted factor was also required. Furthermore, L. reuteri BG-R46®, an evolved strain of DSM 17938 that is known to express higher 5'NT activity, was shown to induce higher levels of melatonin secretion. Taken together, this work identifies zinc and carbon sources as key factors altering L. reuteri 5'NT activity levels and demonstrates that the L. reuteri strains stimulate intestinal melatonin release via 5'NT.
    Keywords:  BG-R46®; DSM 17938; DSM 32846; Limosilactobacillus reuteri; adenosine; carbon utilization; ectonucleotidase; human intestinal organoid; infant colic; maltose; melatonin; pediatric organoid; probiotic; raffinose; stachyose; sucrose; zinc
    DOI:  https://doi.org/10.1080/19490976.2026.2670854